MCM
CYTK icon

MAI Capital Management’s Cytokinetics CYTK Stock Holding History

MAI Capital Management’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-201
Closed -$13.2K – 2689
2026
Q1 		$13.2K Buy
201
+173
+618% +$11K ﹤0.01% 3006
2025
Q4 		$1.78K Hold
28
– – ﹤0.01% 3443
2025
Q3 		$1.54K Sell
28
-199
-88% -$8.2K ﹤0.01% 3375
2025
Q2 		$7.5K Buy
+227
New +$7.9K ﹤0.01% 2875

Other funds holding CYTK

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

MAI Capital Management's CYTK Position: Q2 2026 in Review

MAI Capital Management sold out of Cytokinetics (CYTK) in Q2 2026, closing a stake of 201 shares — an estimated $13.2K sold.

MAI Capital Management first reported a position in CYTK in Q2 2025 and held it in 4 quarters. The position peaked at $13.2K in Q1 2026. 482 funds tracked by Wall St. Rank hold CYTK as of Q2 2026.

  • MAI Capital Management reported no remaining Cytokinetics position as of Q2 2026 after selling out during the quarter.
  • MAI Capital Management sold 201 Cytokinetics shares in Q2 2026, an estimated $13.2K.
  • MAI Capital Management first reported a position in Cytokinetics in Q2 2025 and held it in 4 quarters.
  • MAI Capital Management's Cytokinetics position peaked at $13.2K in Q1 2026.
  • 482 funds tracked by Wall St. Rank held Cytokinetics as of Q2 2026.

Based on MAI Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.